Background: Thyroid cancer is a heterogeneous disease that is classified into differentiated thyroid carcinoma (DTC), undifferentiated/anaplastic thyroid carcinoma (ATC) and medullary thyroid carcinoma. Results of conventional treatment modalities in advanced thyroid cancer have been disappointing and therefore, new therapies are needed.
introduction
Thyroid cancer is the most prevalent endocrine malignancy, estimated to account for 94% of cancers of the endocrine system and 66% of deaths due to cancers of the endocrine system in 2007 [1] . The incidence of thyroid cancer throughout the world is increasing. There is a contribution of improved and more used diagnostic imaging and related 'incidentalomas' that account, at least in part, for the increased incidence. However, the number of patients who die due to this disease also increases. The current incidence in Europe is 40/1 000 000 per year, with a nearly three times higher incidence in women [2] .
Thyroid cancer is a heterogeneous disease that is classified into differentiated thyroid carcinoma (DTC), undifferentiated (anaplastic) thyroid carcinoma (ATC) and medullary thyroid carcinoma (MTC). DTC and ATC together are classified as nonmedullary thyroid cancer (NMTC). See Table 1 for characteristics and prognosis of these subtypes. DTCs are by far the most common (95%), and include papillary (80%) and follicular (10%-15%) as well as subtypes like Hurthle cell carcinomas. The majority of DTCs are slowly progressive, and, when identified at an early stage, frequently cured with adequate surgical management and radioactive iodine 131-I ablation therapy (RAI). Metastatic DTC that has become inoperable or refractory to radioactive iodine therapy, however, is associated with a poor survival ( Table 1) . MTCs and especially ATCs metastasize in up to 50% of patients, thus giving an even worse prognosis [3] . Results of conventional treatment modalities (radiotherapy and/or chemotherapy) have been disappointing and therefore, new therapies are needed. As a result of the increasing knowledge of the biological basis for thyroid cancer development, therapeutic agents that target involved biological abnormalities have been identified. Multiple clinical trials have been carried out in the past decade. In this review, we describe new treatment modalities in differentiated, anaplastic and medullary advanced thyroid cancer.
methods
We searched PubMed, The Cochrane Library. Medline and EMBASE database and abstracts published in annual proceedings for new treatment modalities in advanced thyroid cancer. We also searched for ongoing trials in www.clinicaltrials.gov.
molecular pathogenesis
Nonmedullary thyroid cancer. Studies in benign thyroid cells have shown BRAF to be an important regulator of thyroid-specific protein expression and proliferation [4] . Based on evidence that BRAF is involved in the development of papillary thyroid carcinoma (PTC) and in the progression of anaplastic carcinoma, BRAF is an attractive target in thyroid cancer [5] . BRAF is a putative downstream signal transducer for rearranged during transfection (RET)/PTC. Kebebew et al. [6] reported significant associations of BRAF V600E with recurrent and persistent disease with a higher rate of lymph node metastasis and higher TNM (tumor-nodemetastasis) stage in PTC and follicular variant of PTC.
In a review of 11 studies in thyroid cancer, it was noted that up to 50% of follicular and 12% of Hurthle cell malignancies contained RAS mutations [7] . The RAF proteins are cytoplasmic serine/threonine protein kinases that are downstream effector molecules of RAS. Of these, BRAF is the most efficient at phosphorylating mitogen-activated protein kinase (MAPK) and is important in proliferative as well as apoptotic pathways [8] . Point mutations leading to BRAF signaling independent of binding to RAS have been reported in 35%-70% of PTCs, underlining the significance of the RAS/RAF/MAPK pathway in thyroid cancer [9] . The AKT pathway plays an important role in cell proliferation and survival and has been found by others to be aberrantly activated in thyroid tumors [10] [11] [12] [13] . An important player in this pathway is the PI3KCA subunit that in turn is also regulated by RAS. In a study by Hou et al. [14] , a progressive activation of the PI3K/ AKT pathway and associated methylation of PTEN, known to suppress this pathway, was found in thyroid adenomas, follicular and anaplastic thyroid cancers.
In human thyroid cancer, BRAF V600E is associated with vascular endothelial growth factor (VEGF) overexpression, which in turn is associated with increasing tumor stage and invasiveness [15] . In 1997, Soh et al. observed extensive angiogenesis in thyroid cancer cells that had been xenografted into mice. By using cell lines from human differentiated, medullary and Hurthle cell thyroid cancers, they noted a higher expression of VEGF messenger RNA (mRNA) and protein in thyroid cancer in comparison with normal thyroid tissue [16] .
The most common genetic abnormality in papillary thyroid cancer, occurring in 16%-25% of cases, involves the RET proto-oncogene via rearrangements leading to the fusion of the tyrosine kinase domain to the 5# end of other genes that are constitutively active in follicular thyroid cells. This results in the generation of chimeric oncogenes and proteins denoted RET/PTC whose expression is under the control of promoters provided by the fused genes, leading to ligand-independent activation of RET in papillary thyroid cancer [17] . To date, 12 of these chimeric RET/PTC proteins have been described. medullary thyroid cancer. Activating RET mutations are present in >95% of hereditary MTC cases and in 20%-50% of sporadic MTC cases. Several mutational hotspots of the RET gene have been described to be tumorigenic. Furthermore, a common specific activating point mutation, M918T, appears to be a strong negative prognostic indicator for metastasisfree survival and overall survival (OS). Ten-year survival was 45% in subjects with a confirmed M918T mutation, while it is reported to be as high as 90% in absence of the mutation [18] .
In addition to RET, the VEGF receptor (VEGFR) and MET protooncogene may be implicated in the pathogenesis of MTC. Mutations in the MET RTK have been detected in MTC in one report [19] . Finally, transduction of thyroid cells with mutant RET results in up-regulation of MET [20] . For an overview of the signaling pathways involved in thyroid cancer, see Figure 1 .
new treatment modalities in thyroid carcinoma
As a result of the increasing knowledge of the biological basis for thyroid cancer development, therapeutic agents that target these biological abnormalities have been identified. Multiple clinical trials have been carried out in the past decade (Table 3) .
tyrosine kinase inhibitors. monotarget kinase inhibitors. Gefitinib (ZD1839) is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The EGFR is highly expressed in malignant thyroid tissue and mutations of the EGFR gene have been described in thyroid cancer. Moreover, EGFR contributes to RET activation, signaling and growth stimulation and is associated with poor prognosis in DTC [21] . Pennell et al. studied the effectiveness of gefitinib in a phase II trial with a mixed cohort of thyroid cancer patients. Four percent of patients showed disease reduction. However, this was not qualified as partial response (PR). Overall, 24% of patients achieved stable disease lasting at least 24 weeks. Median progression-free survival (MPFS) was almost 16 weeks, with the exception of MTC patients, in which the median PFS was <12 weeks [22] .
AZD6244 is a potent, selective non-competitive inhibitor of MEK1/2 that has been studied in a phase I study and has shown interesting activity in two advanced thyroid cancer patients with stable disease for at least 5 months [23] . A phase II trial conducted in advanced DTC patients showed a PR in 3% of patients, 66% of patients had stable disease and the median PFS was 32 weeks [24] . multikinase inhibitors. Axitinib (AG-013736) is an oral TKI that effectively blocks all of the VEGFRs. One of five patients with thyroid carcinoma included in a phase I trial experienced tumor shrinkage, which however, was not qualified as a PR [25] . A phase II trial by Cohen et al. [26] studied the efficacy of axitinib in advanced or metastatic thyroid carcinoma of any histology (n = 60). A PR was seen in 30% of the patients. Stable disease lasting >16 weeks was reported in 38%. Objective responses were noted in all histological subtypes with a PR rate of 31% in patients with DTC and 18% in patients with MTC. Median PFS was 18.1 months.
Motesanib (AMG 706) is an oral TKI targeting the VEGFR 1-3, RET and c-KIT. In a phase I trial by Rosen et al. [27] , a 50% overall response rate was observed in patients with advanced thyroid carcinoma. Based on these results, a multicenter phase II trial was initiated, testing the efficacy of motesanib therapy in patients with progressive DTC and progressive or symptomatic MTC. In 14% of the DTC patients, PR was confirmed, and another 35% of these previously progressive patients maintained stable disease for at least 24 weeks. The median response duration was 40 weeks [28] . In a phase II trial in MTC patients by Schlumberger et al. [29] only 6474) is an oral TKI that targets VEGFR 2 and 3, RET and EGFR. Vandetanib effectively inhibits RET/PTC3 chromosomal translocations found in some PTC and M918T RET mutations occurring in MEN2B-associated and some sporadic MTC [30] . In a phase II trial, Wells et al. studied the efficacy of vandetanib in patients with metastatic hereditary forms of MTC. Confirmed PR was reported in 17% of patients, where another 53% had stable disease lasting at least 24 weeks [31] . A second phase II trial in advanced hereditary MTC by Robinson et al. [32] showed a PR rate of 16% and stable disease 24 weeks or longer in 53% of patients. Results of a phase III trial by Wells et al. [33] in locally advanced or metastatic MTC showed an objective response in 43% of patients, all of which were durable. Median PFS was not reached at 24 months of followup.
Sorafenib (BAY 43-9006) is an orally active TKI targeting BRAF, VEGFR 1 and 2 and RET, conducting proapoptotic and antiangiogenic actions. In a phase II study, Gupta et al. [34] found a PR rate of 23% and a stable disease rate of 53% in mainly patients with advanced DTC (n = 30). The median PFS was 79 weeks. Kloos et al. [35] examined the effect of sorafenib mainly in patients with metastatic PTC (n = 41). Of the PTC patients, 15% achieved a PR, whereas 56% had stable disease for at least 24 weeks. The median PFS was 15 months. Hoftijzer et al. [36] carried out a phase II study investigating the efficacy and the question whether sorafenib could reintroduce radioiodine uptake in patients with iodine refractory recurrent or metastatic DTC. Although no reintroduction of radioiodine at metastatic sites was observed, a PR rate was reported in 23% of patients and 39% had stable disease. The median PFS was 58 weeks. Currently, a phase III trial of sorafenib versus placebo is carried out with the possibility of crossover in patients with advanced iodine refractory DTC. In a small pilot study in patients with metastatic MTC, responses were described in 40% of the patients [37] . Lam et al. [38] carried out a phase II trial in which the efficacy of sorafenib in hereditary (arm A) and sporadic (arm B) metastatic MTC patients was examined. They included 16 patients with sporadic MTC. One patient had a PR (6.3%) and 14 patients had stable disease (87.5%). Median PFS was 17.9 months. Arm A was prematurely terminated because of slow accrual.
Sunitinib (SU11248) is an oral TKI of VEGFR 1-3, RET and RET/PTC subtypes 1 and 3. A response rate of 8% in DTC patients and 13% in MTC patients was reported by Ravaud et al. [39] , who carried out a phase II trial to determine the effect of sunitinib in refractory advanced thyroid carcinoma. Furthermore, 67% of DTC patients and 87% of MTC patients showed disease stabilization. In a second phase II trial, Cohen et al. [40] reported a 13% response rate and a 68% stable disease rate in patients with DTC. In MTC patients, responses were observed in 43%, and 83% of patients presented stable disease. Preliminary analysis from a third phase II trial showed PR or stable disease for at least 12 weeks in 17% of DTC and 38% in MTC patients [41] .
Imatinib (STI571) is an oral TKI of BCR-ABL and c-KIT. Its function is based on its inhibition of RET autophosphorylation and RET-mediated cell growth. So far, two small phase II trials that studied the efficacy of imatinib in patients with metastatic MTC have been completed. In both trials, no response was confirmed and only a few patients achieved stable disease [42, 43] . Furthermore, a phase I trial with MTC patients treated with imatinib combined with dacarbazine and capecitabine did not report objective responses [44] .
Pazopanib (GW786034) is an orally bioavailable TKI that targets VEGFR 1-3 and c-KIT. Its antitumor activity in advanced and progressive DTC was demonstrated in a phase II trial. PRs were confirmed in 32% of patients. Median PFS was 12 months [45] . XL184 (Exelixis) is an oral inhibitor of RET, c-MET and VEGFR 1 and 2. c-MET activation triggers tumor growth and angiogenesis. Moreover, in patients with PTC and MTC, overexpression and frequent mutations of the c-MET receptor have been reported [20] . A phase I trial examined the efficacy of XL184 in patients with advanced malignancies, including patients with MTC. In MTC patients with measurable disease, 29% had a confirmed PR and 68% had either confirmed PR or prolonged stable disease ‡6 months [46] . Currently, a phase III trial, comparing XL184 with placebo in patients with advanced MTC, is ongoing.
PLX 4032 is an orally administered small molecule that specifically inhibits only the V600E mutant BRAF kinase, without appreciable impairment of wild-type BRAF or other RAF kinases. Three patients with PTC and documented V600E BRAF mutations have been treated in a phase I study, with one of the three experiencing a PR and the other two having prolonged stable disease [47] .
E7080 is also an inhibitor of multiple TK, especially VEGFRs, c-KIT, platelet-derived growth factor receptor beta stem cell factor receptor. In animal studies, it has been shown to have potent antitumor activity against small cell lung cancer and breast cancer most likely through inhibition of VEGFR-2 and VEGFR-3 [48, 49] . A phase II multicenter trial has been set up to evaluate the safety and efficacy of oral E7080 in medullary and refractory unresectable DTC.
Effectiveness of multitargeted kinase inhibitors can be expressed by IC50 values [the half maximal (50%) inhibitory concentration (IC) of a substance]. Table 2 shows the IC50 values for the most important tyrosine kinase inhibitors and different targets.
other drugs. redifferentiation. Attempts have been made to reinduce the susceptibility to 131 I with retinoids. In four publications, three from the same group, 13-cis retinoic acid therapy increased I-131 uptake in 26%-40% of patients but failed to do so in another study [50] [51] [52] [53] [54] . Chinese investigators treated 11 patients with dedifferentiated thyroid cancer using 1 mg/kg/day of all-trans retinoic acid followed by radioactive iodine. They obtained mixed responses [55] . In a study by Liu et al. [56] , 12 patients with metastases of DTC, with insufficient uptake of I-131, received 6 weeks of treatment with bexarotene. This induced I-131 uptake in metastases in 8 of 11 patients. However, uptake was only discernable at single photon emission computer tomography and had incomplete matching with metastases as visualized by CT scanning. A British study failed to demonstrate clinically significant 131 I uptake after administration of oral isotretinoin [50] .
Perixosome proliferator-activated receptor (PPAR) gamma activation leads to activation of PTEN, which inhibits PI3K. A decreased PPAR gamma expression has been observed in DTC [57] . Therefore, compounds Figure 1 . Signaling pathways involved in thyroid cancer reviews Annals of Oncology agonizing PPAR gamma may be beneficial in DTC. In a small study in five 131-negative patients, rosiglitazone was able to induce radioiodine uptake into metastases in one patient [58] . In two recent studies including more patients, increases in radioiodine uptake after >6 weeks of pretreatment with up to 8 mg of rosiglitazone were observed in 40% and 26% of the patients. However, post-therapy decreases in thyroglobulin levels were only noted in 20% and 17% of cases [59, 60] .
One of the mechanisms by which cells can block the expression of certain genes is by enzymes that methylate these genes or deacetylate the histones that envelope a particular gene. Therefore, compounds that can reverse methylation or inhibit histone deacetylation may lead to the reexpression of genes that are silenced in cancer. In an in vitro study in thyroid carcinoma, the demethylating agent 5-azacytidine led to reinduction of sodium iodide symporter (NIS) expression, accompanied by RaI uptake in thyroid cancer cell lines [61] . In parallel, the histone deacetylase inhibitor depsipeptide has been reported to reinduce NIS mRNA expression and RaI uptake in thyroid carcinoma cell lines and inhibit the growth of several poorly differentiated and anaplastic thyroid cancer cell lines [62, 63] . Depsipeptide has been evaluated in a phase II study with NMTC with the aim of resensitize dedifferentiated tumors to radioiodine therapy. After 2 months, stable disease was reported in 29% of patients. One patient showed clinically significant restoration of RAI avidity [64] . In addition, a similar study by Sherman et al. documented restoration of RAI avidity in 2 of 20 patients. No RECIST major responses have been seen, but stable disease was reported in 10 patients [65] . The orally available histone deacetylase inhibitor vorinostat was studied in 16 DTC patients and 3 MTC patients. No objective responses were reported and most patients discontinued therapy because of adverse events [66] .
Lithium has been reported to increase tumor dosages of RAI in DTC [67] [68] [69] [70] [71] . In a study by Liu et al., the clinical effects of RAI with lithium carbonate were studied in 12 patients with proven metastatic DTC. Despite an increased uptake of RAI in seven patients, no beneficial effect of RAI with lithium was observed on the clinical course as assessed by Tg measurements and radiographically [72] . statins: Statins have been shown to be potent inhibitors of the 3-hydroxy-3-methyl-glutaryl-CoA reductase. In vitro studies show an effect of statins on growth and invasion of tumor cells [73, 74] . Both lovastatin and troglitazone have shown redifferentiating properties, in addition to reduction of growth and invasion of tumors. Glitazones have also been reported to reinduce the expression of NIS [73, 75] .
antiproliferative approaches: In a phase II trial, the efficacy of celecoxib, a selective cyclo-oxygenase-2 inhibitor, was investigated in patients with progressive metastatic DTC. No complete responses were observed. One (3%) patient with PTC achieved a PR at 6 months, which was maintained at 9 months. Twenty-three of 32 patients experienced progressive disease or stopped therapy due to toxicity, thus fulfilling the intent-to-treat study end point for celecoxib failure [76] .
Thalidomide is a glutamic acid derivate with an antiangiogenic effect, presumably by modeling tumor necrosis factor-a and blocking VEGFR and basic fibroblast growth factor. However, its precise action mechanism is unknown. A phase II trial was set up to study the effectiveness of thalidomide in patients with progressive metastatic thyroid carcinoma. Overall, 18% achieved a PR and 32% showed stable disease. PR or durable stable disease was seen in 38% of DTC and 15% of MTC patients [77] .
Lenalidomide (CC-5103) is a thalidomide derivate with a less toxic profile. Ain et al. [78] carried out a phase II trial with lenalidomide in patients with rapidly progressive and iodine refractory DTC patients. They reported a response rate in 23% of patients, and another 45% showed disease stabilization. However, median OS was <11 months.
The mechanism of the proteasome inhibitor bortezomib is complex but includes the inhibition of IkBa degradation, which leads to inactivation of nuclear factor kappa-light-chain-enhancer of activated B cells. The drug has been shown to have an effect on the growth in ATC cell lines alone and in combination with other drugs [79, 80] . The efficacy of bortezomib is currently being studied in DTC patients not responding to radioactive iodine therapy.
Combrestatin A4 phosphate is a novel drug whose precise mechanism is unknown. It is structurally similar to colchicine and causes antitumor effects by binding tubulin and disrupting vascular supply within tumors. When given to patients with advanced cancer in a phase I trial, a single patient with ATC had a complete response that lasted >30 months after treatment [81] . Preliminary data from a subsequent phase II study in 26 ATC patients failed to obtain any objective responses, but seven patients achieved disease stabilization for 12 months [82] . A phase III of this agent in combination with carboplatin and paclitaxel (Taxol) chemotherapy is currently accruing.
A small molecule (JNJ-26854165) that is able to stabilize Hdm2-p53 after its ubiquitation and save the complex from proteosomal degradation is currently in a phase I trial and has shown significant activity not only in wild-type p53 tumors but also in mutant cell lines. Long-term stabilization has been observed in a patient with previously progressive Hurthle cell carcinoma [83] . Currently, several trials are ongoing with this and other compounds that are also able to inhibit Hdm2, such as Nutilins, and planned phase II trials in specific tumor types alone or in combination with cytostatics will be initiated in the near future.
Currently, 17-AAG (17-allylamino-17-demethoxygeldanamycin) is studied in patients with inoperable or metastatic thyroid carcinoma including MTC. 17-AAG induces inhibition of heat shock protein 90 (HSP90), a molecular chaperone needed for optimum activity of oncogenic Gefitinib  ------EGFR-R  33  Motesanib  2  3  6  59  --C-KIT  8  Sorafenib  -90  20  47  50  22  C-KIT  8  Sunitinib  2  9  17  41  224  -Vandetanib  1600  40  110  130  100  -EGFR  500  XL184  -0.035  -4  --C-MET  1.8 protein kinases. It has been demonstrated in vitro that inhibition of HSP90 alters the biology of thyroid cells with rearranged RET [84] .
In cell lines and in xenograft models, inhibition of farnesyl protein transferase (FTPase) activity by manumycin, a specific inhibitor of FTPase, has shown antineoplastic properties inhibiting RAS signal transduction pathway and inducing apoptosis [85] . Manumycin has not reached the clinical setting due to its significant toxicity in animal models, but several FTPases inhibitors, such as tipifarnib and lonafarnib, are currently in clinical development. As a single agent, FTPase inhibitors have shown little clinical activity in human solid tumors, but in a phase I trial that is currently evaluating the combination of tipifarnib and sorafenib, a PR in an MTC patient was reported [86] . Recently, a phase II trial with RAD001, an agent that inhibits mammalian target of rapamycin (MTOR), started in our center, investigating the efficacy of RAD001 in patients with progressive unresectable recurrent or metastatic DTC, MTC and ATC. Results are expected beginning/medio 2012. Other agents under investigation can be found on www.clinicaltrials.gov.
Results of clinical trials with tyrosine kinase inhibitors and other drugs in thyroid carcinoma are shown in Table 3 .
other therapies in DTC and MTC. Gene therapy can be particularly attractive for the treatment of thyroid cancer because of the possibility of selecting targeting of therapeutic genes to tumor cells by application of tissue-specific promoters, such as the thyroglobulin and calcitonin promoter. The gene therapy approaches that have been investigated in thyroid cancer are corrective gene therapy, cytoreductive gene therapy and immunomodulatory gene therapy. Studies in tumor models of dedifferentiated and medullary thyroid cancer have demonstrated that sodium iodide symporter (NIS) is a potential novel reporter and therapy gene that can pave the way for the development of a highly promising cytoreductive gene therapy strategy [89] .
In addition, immunotherapy with dendritic cells has been successfully evaluated in a transgenic mouse model for MTC and this approach has occasionally been tested in humans [90] . However, a robust effect has not been demonstrated [91, 92] .
In most of the patients with progressive metastatic (or recurrent) radioiodine-refractory DTC, uptake of radiolabeled somatostatin analogs is evident on somatostatin-receptor scintigraphy (SRS) [93, 94] . Using SRS, patients with sufficient uptake of radiolabeled somatostatin analogs can be selected for high-dose peptide receptor radionucleotide therapy (PRRT) as an alternative targeted-treatment option. PRRT with the b-particleemitting radionucleotides 90 Yttrium ( ) give the best results in terms of objective tumor response [95] [96] [97] [98] [99] [100] [101] [102] [103] . Promising, novel radiolabeled somatostatin analogs that have a broader receptor affinity profile and, thus, a potentially wider therapeutic range are being tested clinically [104] .
discussion
In this review we have described new treatment modalities in DTC, ATC and MTC advanced thyroid cancer. The large majority of patients with DTC can be cured, and others may survive for decades despite persistent disease. However, DTC patients with progressive radioiodine-resistant metastatic disease have a worse prognosis and the results of conventional treatment modalities (radiotherapy and/or chemotherapy) (18) have been disappointing. These patients should nowadays be considered for entry into clinical trials with new agents. With the new agents currently available, also advanced MTC patients seem to have a much better perspective. For ATC patients, hopefully, targeted therapy will be the clue for better treatment since this devastating disease has shown to be almost therapy resistant. The large development in the treatment of advanced thyroid cancer is due to the unraveling of the carcinogenesis of thyroid cancer. Aberrations in RET/PTC-RAS-RAF-MAPK pathway are present in a high percentage of thyroid cancer, and there are also angiogenesis switch alterations and involvement of other receptor tyrosine kinases, such as EGFR or c-Met. Because of the oncogenic roles of activated BRAF, RET and RET/PTC kinases, and RET/PTC kinases, the assumption was that specific targeting of these kinases could block tumor growth and induce senescence [105] . As can be shown from multiple clinical trials in thyroid cancer, these assumptions have appeared to be correct. Several promising agents have been found in DTC and MTC (Table 3) . However, the search for new agents in sequential or combination therapy will still be necessary since patients eventually become progressive on these agents or do not tolerate them.
However, there are some issues that need attention. A substantial proportion of patients (33%-50%) have stable disease of varying duration as best response in several studies. Given the indolent natural history of many of these tumors, a report of stable disease is of limited value. In this context, the determination of the best primary endpoint stays an issue. Objective response rates give information on progression, stabilization or shrinkage of tumors within a certain period of time, but do not correlate per se with OS. Progression-free survival or OS are not always preferred primary end points in advanced thyroid cancer because of its indolent nature. Furthermore, the RECIST criteria may not be the best method for tumor evaluation in this tumor type since anatomical imaging alone may have limitations. Only patients with documented progressive disease should be included in clinical trials. If this is not the case, the value of achieving stable disease is even further undermined and hereby differences in outcomes between studies may develop. Furthermore, if there are beneficial effects of therapy on tumor response, they must always be weighed against the side-effects of targeted therapies and hence its influence on quality of life. The side-effects of several tyrosine kinase inhibitors are shown in Table 4 .
In conclusion, the developments in the treatment of advanced thyroid cancer are intriguing. The unraveling of the molecular pathways in thyroid cancer has played a pivotal role in the development of targeted therapy for thyroid cancer. Issues that need to be further addressed are which radiological examination should be used for detection and monitoring of advanced disease, which response evaluation criteria are most suitable, what is the optimal timing of starting therapy and which primary end point should be used in clinical studies. Furthermore, to increase the accrual of patients in clinical studies, to optimize the design of protocols, to improve the characterization of tumor tissues and to improve the tolerance of treatment, a multidisciplinary team of medical oncologists, endocrinologists, specialists in nuclear medicine, radiologists, surgeons, pathologists, molecular biologists and statisticians is highly recommended.
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